Formulation

Why we shouldn’t forget gelatin’s longstanding reputation as a reliable and trusted excipient.

The end of “mini me” medicine is over, says Andrew Parker, because we can do better when it comes to pediatric care.

Products are becoming increasingly complex and we need to get better at recognizing the strategies with the best advantages.

Antibody drug conjugates have not yet lived up to their potential, but there is hope – if we turn to the right solutions and techniques.

Rare diseases aren’t the only field that can benefit from repurposing – the eye is also often overlooked.

Drug repurposing can benefit many areas of drug discovery – particularly rare diseases.

For inhaler technology to evolve, questions about efficacy must be answered.

The Medicine Maker's James Strachan speaks with Paul Evans from Johnson Matthey.

The Medicine Maker's William Aryitey speaks with Dago Caceres from Dow Pharmaceuticals.

The Medicine Maker's James Strachan speaks with Francois Scheffler from BASF.